Moore RD - Search Results

1

Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil.

Cardoso SW, Grinsztejn B, Velasque L, Veloso VG, Luz PM, Friedman RK, Morgado M, Ribeiro SR, Moreira RI, Keruly J, Moore RD. Cardoso SW, et al. Among authors: moore rd. AIDS Res Hum Retroviruses. 2010 Aug;26(8):865-74. doi: 10.1089/aid.2009.0274. AIDS Res Hum Retroviruses. 2010. PMID: 20672997

2

Association of medical insurance and other factors with receipt of antiretroviral therapy.

Keruly JC, Conviser R, Moore RD. Keruly JC, et al. Among authors: moore rd. Am J Public Health. 2002 May;92(5):852-7. doi: 10.2105/ajph.92.5.852. Am J Public Health. 2002. PMID: 11988459 Free PMC article.

3

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

4

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

5

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

6

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

7

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Gallant JE, Parish MA, Keruly JC, Moore RD. Gallant JE, et al. Among authors: moore rd. Clin Infect Dis. 2005 Apr 15;40(8):1194-8. doi: 10.1086/428840. Epub 2005 Mar 17. Clin Infect Dis. 2005. PMID: 15791522 Clinical Trial.

8

An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Moore RD, Keruly JC, Gebo KA, Lucas GM. Moore RD, et al. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):195-8. J Acquir Immune Defic Syndr. 2005. PMID: 15905736

9

Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.

Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: moore rd. Am J Epidemiol. 2006 Mar 1;163(5):412-20. doi: 10.1093/aje/kwj059. Epub 2006 Jan 4. Am J Epidemiol. 2006. PMID: 16394200

10

Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003.

Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Barry PM, et al. Among authors: moore rd. AIDS. 2006 Feb 14;20(3):437-44. doi: 10.1097/01.aids.0000206507.54901.84. AIDS. 2006. PMID: 16439878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

924 results

Search Page

Filters